Mobile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis- Associated Pain

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-004295-11

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the safety, tolerability and efficacy of elagolix (ABT-620), administered once daily (QD) or twice daily (BID) for 3 months in the management of moderate to severe endometriosis-associated pain, and to evaluate the effect of elagolix treatment on analgesic use for endometriosis-associated pain.

Critère d'inclusion

  • Moderate to Severe Endometriosis Associated Pain

Liens